Ascendis Pharma A/S (ASND)
253.38
+1.43
(+0.57%)
USD |
NASDAQ |
Aug 25, 16:00
253.38
0.00 (0.00%)
After-Hours: 19:59
Ascendis Pharma Gross Profit Margin (Quarterly) : 90.64% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 90.64% |
| March 31, 2026 | 91.37% |
| December 31, 2025 | 88.91% |
| September 30, 2025 | 87.87% |
| June 30, 2025 | 77.67% |
| March 31, 2025 | 78.59% |
| December 31, 2024 | 89.95% |
| September 30, 2024 | 74.61% |
| June 30, 2024 | 62.65% |
| March 31, 2024 | 88.27% |
| December 31, 2023 | 82.26% |
| September 30, 2023 | 74.74% |
| June 30, 2023 | 62.92% |
| March 31, 2023 | 72.71% |
| December 31, 2022 | 77.67% |
| September 30, 2022 | 59.40% |
| June 30, 2022 | 11.09% |
| March 31, 2022 | -26.84% |
| December 31, 2021 | -59.22% |
| September 30, 2021 | 0.00% |
| June 30, 2021 | 0.00% |
| March 31, 2021 | 0.00% |
| December 31, 2020 | 0.00% |
| September 30, 2020 | 0.00% |
| June 30, 2020 | 0.00% |
| Date | Value |
|---|---|
| March 31, 2020 | 0.00% |
| December 31, 2019 | 0.00% |
| September 30, 2019 | 0.00% |
| June 30, 2019 | 0.00% |
| March 31, 2019 | 0.00% |
| December 31, 2018 | 0.00% |
| September 30, 2018 | 0.00% |
| June 30, 2018 | 0.00% |
| March 31, 2018 | 0.00% |
| December 31, 2017 | 0.00% |
| September 30, 2017 | 0.00% |
| June 30, 2017 | 0.00% |
| March 31, 2017 | 0.00% |
| December 31, 2016 | 0.00% |
| September 30, 2016 | 0.00% |
| June 30, 2016 | 0.00% |
| March 31, 2016 | 0.00% |
| December 31, 2015 | 0.00% |
| September 30, 2015 | 0.00% |
| June 30, 2015 | |
| March 31, 2015 | |
| December 31, 2014 | 95.22% |
| September 30, 2014 | 96.19% |
| June 30, 2014 | 0.00% |
| March 31, 2014 | 0.00% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Evaxion AS | -- |
| Genmab A/S | 92.73% |
| Zealand Pharma A/S | 99.76% |
| Cellectis SA | 15.62% |
| BioMarin Pharmaceutical, Inc. | 72.27% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | 272.7% |
| Return on Assets | 47.69% |
| Return on Invested Capital | 71.66% |
| Profit Margin (Quarterly) | 61.00% |
| Operating Margin (Quarterly) | 18.39% |
| Return on Net Operating Assets | 119.6% |